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tient stay were linked. Their overall survival data were presented as product-limit 
survival probabilities. Results: There were 240 to 290 new cases annually between 
2006 and 2011. The raw incidence rate was about 1.1 to 1.26 per 100,000 persons,. 
The age adjusted incidence rate was around 1.5 per 100,000 persons. This was much 
lower than that the overall incidence in the US (21.1 per 100,000 per year). But it was 
similar to that of Asia-Pacific islanders in the US. The proportion of death between 
2006 and 2011 were 28.8% and 21.9% among males and females respectively. This 
was different from the US population, whose 5 year survival was 91.3%. The popula-
tion composition of the US was different from that in Taiwan and thus cannot be 
compared directly. About 29% of Taiwan patients were farmers. The mortality of 
farmers (36.5%) was slightly higher than that of non-farmers (22.4%). After control-
ling for age and sex, the hazard ratio of farmer vs. non-farmers was 1.136. Their age 
of diagnosis was much higher than the non-farmers: 82% and 34% for farmers and 
non-farmers diagnosed at age 65 and above, respectively. ConClusions: Malignant 
melanoma is found to be a rare but deadly disease in Taiwan. One reason for low 
survival probability was that farmers delayed the diagnosis to old age. It is suggested 
to screen farmers in early age.
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objeCtives: The Food and Drug Administration (FDA) have approved 28 oncolog-
ics across 37 indications on the basis of pivotal Phase II data lacking an active 
comparator (Macaulay, ISPOR Toronto 2014). Approval was typically granted for 
indications with therapeutic alternative where a response rate ≥ 10% was demon-
strated. This research aims to define the circumstances under which oncologics 
can obtain both regulatory approval and public reimbursement in Australia on this 
basis. Methods: Public Summary Documents (PSDs) were extracted for any onco-
logic indication appraised by the FDA on pivotal Phase II data and the Therapeutic 
Goods Administration (TGA) and Pharmaceutical Benefits Advisory Committee 
(PBAC) decision and key rationale were extracted. Results: 3 oncologics across 7 
oncology indications (nilotinib in chronic myelogenous leukemia, dasatinib in acute 
lymphoblastic leukaemia (ALL), imatinib in ALL, dermatofibrosarcoma protuberans, 
myelodysplastic syndrome/ myeloproliferative disease and hypereosinophilic syn-
drome and/or chronic eosinophilic leukemia, and aggressive mastocytosis) have 
been granted TGA and PBAC approval on pivotal Phase II data. 2 were TGA approved 
but PBAC rejected (bevacizumab and cetuximab), 3 were submitted to PBAC on 
Phase III data, and no PSDs were extractable for the remaining 26 indications. In 
7/7 approved indications, PBAC recognized active comparator alternatives. In 4/7, 
the rarity of these indications was cited as a key mitigating factor. For 2/7, overall 
survival (OS) data was presented that indicated potentially substantial OS benefits. 
In 1/7, a cost-minimisation argument was accepted against a recently approved 
comparator. Of the PBAC-rejected drugs, cetuximab raised key concerns over a lack 
of OS data, while significant trial comparability issues were expressed with beva-
cizumab. All PBAC-approved submissions included economic modelling on a cost/
benefit, not cost/QALY, approach. ConClusions: PBAC can recommend the reim-
bursement of oncologics that offer potentially substantial clinical benefits based 
on an indirect comparison of single arms trials with acceptable cost-effectiveness 
as demonstrated on a cost-benefit metric.
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objeCtives: Organised, nationwide screening for breast cancer with mammogra-
phy in the age group 45-65 years with 2 years screening interval started in Hungary 
in January 2002. According to the Hungarian guideline on mammography screening, 
an accredited mammography screening centre should perform 10000 examinations 
annually. The aim of this study is to analyze the quality control indicators of this 
screening programme. Methods: The data derive from the financial database of 
the National Health Insurance Fund Administration (NHIFA) covering the period 
2002-2010 year. We analysed 3 selected years: 2002, 2005 and 2010. The main indica-
tor was the number of mammography screening examinations performed by the 
mammography screening centres. Results: The annual number of mammography 
examinations was 323537 in 2002, 247045 in 2005 and 242601 in 2010. The number 
of accredited mammography screening centres were 51 (2002), 41 (2005) and 40 
(2010). The average number of mammography examinations were 6344 (2002), 6025 
(2005) and 6065 (2010) per year. In 2002, 14 mammography centres performed 10000 
examinations in a range from 10314 to 25940. In 2005 only 4 mammography centres 
achieved more than 10000 examinations per year (range: 10294-17845). In 2010 again 
only 4 mammography centres achieved more than 10000 examinations per year 
(range: 10239-19259). ConClusions: Only a few number of mammography centres 
met the recommendation of the Hungarian mammography screening guideline 
and reached the target (10000 mammography examinations annually). Most of the 
mammography centres are not able to comply with professional guideline.
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vitro dissolution study in three different solvents such as hydrochloric acid pH 1.5, 
artificial saliva pH 6.7 and saline phosphate buffer solution pH 7.4 respectively. And 
drug release from the in vitro dissolution study. Results: The result reveals that 
prepared formulation F6 shown maximum value. The ex vivo permeation studies 
of Fluconazole drug through porcine buccal mucous membrane were performed 
and the results shown that F6 formulation was the best formulation among the 
prepared mouth dissolving tablets. ConClusions: Thus, the prepared (F6 formula-
tion) mouth dissolving tablets had both local and systemic action and may be used 
for treating oropharyngeal and esophageal candidiasis (oral candidiasis) mainly as 
ulcer, burning sensation of buccal cavity particularly in premature infants, geriatric 
bed ridden patients, and patients with weak immune system caused by cancer 
treatment or diseases such as AIDS.
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objeCtives: The purpose of this study was to evaluate the reduction in average 
market entry timelines for oncology agents in Italy if approved by AIFA as “C(nn)” 
class (non-negotiated class under the 189/2012 law) as compared to “A” (fully reim-
bursed) / “H” (hospital reimbursement). Methods: For the purpose of this study, 
only the approval of the agents’ first indications were taken into consideration. 
Included in this study were C(nn) oncology agents approved between May 27, 2013 
and February 27, 2014 (aflibercept, pertuzumab, bosutinib, enzalutamide, vismo-
degib, pomalidomide, regorafenib, dabrafenib, infliximab, afatinib, radium Ra223 
dichloride, trastuzumab emtansine) and class “A” / “H” agents approved between May 
27, 2010 and December 2, 2013 (everolimus®, denosumab, pazopanib, cabazitaxel, 
denosumab, abiraterone, vemurafenib, vandetanib, axitinib). The average time to 
approval was calculated as the average difference between the date of issue of EMA 
marketing authorization and the determination date (“determina”) in the Italian 
“Gazzetta Ufficiale”. Results: The average time to reimbursement for oncology 
agents from EMA marketing authorization to AIFA approval as “C(nn)” class was 
estimated as 111.3±39.9 days (n= 12), while the average time to reimbursement as 
either “A” or “H” class was estimated as 428.3±109.0 days (n= 9). This represents a 
significantly faster approval process (unpaired t-test, p< 0.01), where on average, the 
C(nn) approval process is faster by 317 days. ConClusions: This study shows that 
time to reimbursement for oncology agents from EMA marketing authorization to 
AIFA approval is significantly expedited through the use of “C(nn)” classification, 
reducing market entry timelines by nearly a full year (317 days) compared to the 
regular “A” or “H” class approval process. Pharmaceutical companies seeking expe-
ditious market entry into Italy for a newly approved oncology therapy targeting an 
area of high unmet need should therefore consider applying for C(nn) class.
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objeCtives: To optimize access to cancer therapy in Asia Pacific (AP) nowadays 
became challenging due to budget constraints. Different decisions were made due 
to individual context, health care system and evidence required to support the 
decision. This study reviewed coverage decisions made by government in AP using 
targeted cancer medicines as a case study. Methods: We selected 6 targeted cancer 
medicines recommended for breast cancer treatment based on the 2013 national 
comprehensive cancer network guidelines. Eight AP countries with different health 
coverage system were included to highlight the differences of health coverage sys-
tem on decisions: four reimbursement countries [Australia (AUS), South Korea (KE), 
Taiwan (TW) and Japan (JP)] and four partial reimbursement countries [Malaysia 
(MY), Thailand (TH),China (CN) and Hong Kong (HK)]. We identified data from mul-
tiple sources including “Pubmed”, government websites, payers and companies 
from inception till Jan 2014. We compared health coverage features, oncology cov-
erage list and evidence requirement for decision making. Based on HTA approach, 
six possible supporting factors were compared. They included burden of disease, 
clinical effectiveness, economic evaluation (EE), budget impact analysis (BIA), public 
health impact, ethical concern and availability of alternative treatments. Results: 
Efficacy and safety data were used as decision factors in all countries. AUS, KE, TW 
and TH considered both EE and BIA. AUS, KE and TH required local HTA evidence 
.Of six medicines, trastuzumab is now covered in most countries: AUS, MY, TW 
and KE. However, limited information is publicly available on evidence used in 
coverage decision in most countries except AUS where all factors except public 
health impact and ethical issue consideration are documented. ConClusions: 
Coverage decisions are affected by health care system and HTA evidence. Limited 
public documents related to coverage decisions are available. HTA system may lead 
to the development of explicit decision framework criteria for coverage decisions.
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objeCtives: To understand the incidence, prevalence, and survival probability in 
the whole population in Taiwan. Methods: This study utilized the 2005 to 2011 
National Health Insurance (NHI) Research Database to study the disease. Inclusion 
criterion was that patients had at least two outpatient visits or one inpatient stay for 
melanoma (ICD9 code: 172). Patients’ medical orders for outpatient visits and inpa-
